Alkem Laboratories enters its Q1 FY27 results following a year of leadership transition and strategic expansion into the medical devices sector. Investors are looking for clarity on how the company's domestic branded-generics growth is tracking against a robust Indian Pharmaceutical Market, alongside the margin impact of raw material cost headwinds and the recent USFDA classification of its Daman facility.
| Results date | August 14, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 36,033 Mn |
| Previous quarter PAT | Rs. 2,365 Mn |
| Previous quarter EBITDA margin | 14.4% |
| Net debt (latest quarter) | Rs. 54.74 Bn |
| Market cap | Rs. 65,156.95 Cr |
| CMP | Rs. 5,449.5 |
The Board Meeting is scheduled for August 14, 2026, to approve the Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2026.
A conference call is scheduled for August 14, 2026, at 4:30 PM IST, hosted by Motilal Oswal Securities, with MD Sandeep Singh and CFO Nitin Agrawal representing the company.
Domestic branded-generics revenue is expected to outpace the broader Indian Pharmaceutical Market, which grew at 10.3–12% through April and May 2026, supported by Alkem's chronic therapy mix reaching 22% of branded generics. While the weakening rupee provides a tailwind to INR-reported US revenue, the Daman facility's OAI classification and ongoing base-pricing erosion of 3–4% may temper growth compared to the 26% YoY increase seen in Q4 FY26. EBITDA margins are expected to be pressured relative to the 21.9% reported in Q1 FY26 due to the impact of Minimum Import Price (MIP) costs on PenG and higher R&D spending, though management aims to maintain the 20–21% band for the full year. Investors should monitor the normalization of the effective tax rate, which stood at 15.4% in the year-ago quarter, as a potential headwind to bottom-line growth.
Performance vs Guidance Tracking: Management's progress against key annual targets for FY27.
Strategic Initiatives and Capex: Updates on recent acquisitions and CDMO operations.
Risks and Headwinds to Monitor: Management-flagged operational and regulatory challenges.
The USFDA classified the Daman (Amaliya) facility as Official Action Indicated (OAI) on August 6, 2026, following a 7-observation Form 483. The company stated that manufacturing for the US market will continue while it works toward full compliance.
Alkem achieved an overall domestic outperformance of 20 bps over the Indian Pharmaceutical Market (IPM) in FY26. While the acute segment outperformed by 170 bps, the chronic segment saw a 10 bps outperformance.
Alkem Medtech completed the acquisition of a 51-55% stake in the Swiss company Occlutech Holding AG on July 17, 2026. The acquisition was funded by a Rs. 1,100 Cr rights issue in Alkem Medtech.